Leukotriene-lipoxygenase pathway and drug discovery

Folia Pharmacologica Japonica

Volumn 124, Issue 6, 2004, Pages 415-425

  Abe, Masayoshi ^a   Yoshimoto, Tanihiro ^b  

^a FUKUOKA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Asthma; Atherosclerosis; Cysteinyl leukotriene receptor; Leukotriene; Lipoxygenase

Indexed keywords

6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; ANTIASTHMATIC AGENT; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ATRELEUTON; BAICALEIN; CAFFEIC ACID; CIRSILIOL; CYSTEINYLLEUKOTRIENE TYPE 1 RECEPTOR; CYSTEINYLLEUKOTRIENE TYPE 1 RECEPTOR ANTAGONIST; CYSTEINYLLEUKOTRIENE TYPE 2 RECEPTOR; DOCEBENONE; ESCULETIN; ICOSATETRAYNOIC ACID; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; NORDIHYDROGUAIARETIC ACID; PD 146176; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; QUERCETIN; SLOW REACTING SUBSTANCE; STEROID; THUJAPLICIN; UNCLASSIFIED DRUG; ZILEUTON;

ASTHMA; ATHEROSCLEROSIS; CLINICAL PRACTICE; DISEASE COURSE; DRUG MECHANISM; DRUG STRUCTURE; HEART ARRHYTHMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; MOLECULAR CLONING; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; REVIEW;

ANTI-ASTHMATIC AGENTS; ARTERIOSCLEROSIS; DRUG DESIGN; HUMANS; LEUKOTRIENES; LIPOXYGENASE;

EID: 10944246663     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.124.415     Document Type: Review

References (87)

1. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol. 2004;73:1503-1510.
2. Chanez P, Caroline B, Chavis C, Vachier I. 15-Lipoxygenase; a janus enzyme? Am J Respir Cell Mol Biol. 2002;27:655-658.
3. Zhu H, Takahashi Y, Xu W, Kawajiri H, Murakami T, Yamamoto M, et al. Low density lipoprotein receptor-related protein-mediated membrane translocation of 12/ 15-lipoxygenase is required for oxidation of low density lipoprotein by macrophages. J Biol Chem. 2003;278:13350-13355.
4. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA. 2003; 100:1238-1243.
5. Feldberg W, Kelloway CH. Liberation of histamine and formation of lysolecithin-like substance by cobra venom. J Physiol (Lond). 1938;94:187-226.
6. Brocklehurst WE. The release of histamine and formation of a slow reacting substance (SRS-A) during anaphylactic shock. J Physiol (Lond). 1960;151:416-435.
7. Augstein J, Farmer JB, Lee TB, Sheard P, Tattersall ML. Selective inhibitor of slow reacting substance of anaphylaxis. Nat New Biol. 1973;245:215-217.
8. Murphy RC, Hammarström S, Samuelsson B. Leukotriene C. A slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA. 1979;76:4275-4279.
9. Lewis RA, Austen KF, Drazen JM, Clark DA, Marfat A, Corey EJ. Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci USA. 1980;77:3710-3714.
10. 4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol. 1989;84:19-26.
11. 4-receptor antagonist. N Engl J Med. 1990; 323:1736-1739.
12. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991;337:690-694.
13. Israel E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold air. N Engl J Med. 1990;323:1740-1744.
14. Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis. 1993;148:1447-1451.
15. Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 2003;58:211-216.
16. Dempsey OJ, Wilson AM, Sims EJ, Mistry C, Lipworth BJ. Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. Chest. 2000;117:950-953.
17. 1 receptor. Nature. 1999;399:789-793.
18. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, et al. Characterization of the human cysteinyl leukotriene 2 receptors. J Biol Chem. 2000;275:30531-30536.
19. Capra V. Molecular and functional aspects of human cysteinyl leukotriene receptors. Pharmacol Res. 2004;50:1-11.
20. Maekawa A, Austen KF, Kanaoka Y. Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J Biol Chem. 2002;277:20820-20824.
21. 1R. Proc Natl Acad Sci USA. 2003;100:11589-11593.
22. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl J Med. 1990;323:645-655.
23. 4 receptor antagonist. Respir Med. 1998;92:1084-1086.
24. Bisgaard H. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med. 2003;167:379-383.
25. Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med. 2004;350:735-736.
26. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med. 2002;347:1493-1499.
27. Gorenne I, Norel X, Brink C. Cysteinyl leukotriene receptors in the human lung: what's new? Trends Pharmacol Sci. 1996;17:342-345.
28. Sur S, Crotty TB, Kephart GM, Hyma BA, Colby TV, Reed CE, et al. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis. 1993;148:713-719.
29. Di Gennaro A, Carnini C, Buccellati C, Ballerio R, Zarini S, Fumagalli F, et al. Cysteinyl-leukotrienes receptor activation in brain inflammatory reactions and cerebral edema formation: a role for transcellular biosynthesis of cysteinyl-leukotrienes. FASEB J. 2004;18:842-844.
30. Evans JF. Cysteinyl leukotriene receptors. Prostaglandins Other Lipid Mediat. 2002;68-69:587-597.
31. Tudhope SR, Cuthbert NJ, Abram TS, Jennings MA, Maxey RJ, Thompson AM. BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes. Eur J Pharmacol. 1994;264:317-323.
32. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983;220:568-575.
33. 4 synthetase of rat basophilic leukemia cells: a novel, particulate glutathione S-transferase. Arch Biochem Biophys. 1984; 230:455-465.
34. 4 synthetase. Biochem Biophys Res Commun. 1985; 127:15-23.
35. 4 synthase activity in thioglycollate-elicited peritoneal macrophages. Biochem Biophys Res Commun. 1990;171:1344-1352.
36. 4 synthase expression in dimethyl sulfoxide-differentiated U937 cells. J Biol Chem. 1992;267:17849-17857.
37. 4 synthesis in rat basophilic leukemia-1 cells. Am J Respir Cell Mol Biol. 1994;11:49-56.
38. 4 synthase after the differentiation of rat basophilic leukemia cells with retinoic acid and a low dose of actinomycin D and its suppression with methylprednisolone. J Cell Physiol. 2003;196:154-164.
39. 4 synthase from dimethylsulfoxide-differentiated U937 cells. Eur J Biochem. 1992;209:725-734.
40. 4. Proc Natl Acad Sci USA. 1994;91:7663-7667.
41. 4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest. 1998;101:834-846.
42. 4 synthase. J Biol Chem. 2002;277:28902-28908.
43. 4 synthase. J Biol Chem. 2001;276:22608-22613.
44. 4 antagonism. In: Hansel TT, Barnes PJ, editors. Progress in respiratory research. Vol. 31, New drugs for asthma, allergy and COPD. Tokyo: Karger Tokyo; 2001. p.121-125.
45. 4 that mediates chemotaxis. Nature. 1997;387:620-624.
46. 4 receptor, BLT2: a new therapeutic target in inflammation and immunological disorders. J Exp Med. 2000;192:421-431.
47. 4 receptor antagonist LY293111: in vivo pulmonary studies. Naunyn Schmiedebergs Arch Pharmacol. 2000;361:397-404.
48. 4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax. 1996;51:1178-1184.
49. 4 antagonists in the mouse ear edema and rat neutropenia models. Inflamm Res. 1995;44:S141-142.
50. 4 receptor antagonist on antigen-induced pulmonary reaction. Eur J Pharmacol. 1999;370:153-159.
51. 4 receptor antagonist with oral anti-inflammatory activity. J Med Chem. 1996;39:3837-3841.
52. 4 receptor antagonist with anti-inflammatory activity. Prostaglandins Leukot Essent Fatty Acids. 1999;61:55-64.
53. 4 antagonist CP-195543. J Pharmacol Exp Ther. 1998; 285:946-954.
54. 4 receptor antagonist SC-53228 on ozone-induced airway hyperresponsiveness and inflammation in dogs. Am J Respir Crit Care Med. 1995;152:1443-1448.
55. 4 receptor antagonist. J Pharmacol Exp Ther. 2001;297:458-466.
56. 4 hydrolase. Bioorg Med Chem. 1995;3:969-995.
57. 4 hydrolase. Biochem Biophys Res Commun. 1990;171:216-221.
58. 4 hydrolase: a zinc metalloenzyme. Biochem Biophys Res Commun. 1990;172:965-970.
59. 4 hydrolase inhibitors. J Med Chem. 1992; 35:3156-3169.
60. 4 in vitro and in vivo. J Immunol. 1994;153:5750-5759.
61. 4) hydrolase. J Med Chem. 2000;43:721-735.
62. 4 hydrolase 1: in vitro studies. J Pharmacol Exp Ther. 2002;300:577-582.
63. 4 hydrolase 1: in vivo studies. J Pharmacol Exp Ther. 2002;300:583-587.
64. 4 hydrolase in complex with captopril and two competitive tight-binding inhibitors. FASEB J. 2002;16:1648-1650.
65. Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature. 1990;343:282-284.
66. Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Matzke M, Pleiss U, et al. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X1005: implications for biological regulation of 5-lipoxygenase. Agents Actions. 1994;43:64-68.
67. McGill KA, Busse WW. Zileuton. Lancet. 1996;348:519-524.
68. 2 and platelet aggregation in patients with asthma. Am J Hematol. 2003;74:23-25.
69. Ashida Y, Saijo T, Kuriki H, Makino H, Terao S, Maki Y. Pharmacological profile of AA-861, a 5-lipoxygenase inhibitor. Prostaglandins. 1983;26:955-972.
70. Koshihara Y, Neichi T, Murota S, Lao A, Fujimoto Y, Tatsuno T. Caffeic acid is a selective inhibitor for leukotriene biosynthesis. Biochim Biophys Acta. 1984;792:92-97.
71. Reid JJ. ABT-761 (Abbott). Curr Opin Investig Drugs. 2001;2:68-71.
72. Fischer L, Steinhilber D, Werz O. Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Br J Pharmacol. 2004;142:861-868.
73. McAlexander MA, Myers AC, Undem BJ. Inhibition of 5-lipoxygenase diminishes neurally evoked tachykinergic contraction of guinea pig isolated airway. J Pharmacol Exp Ther. 1998;285:602-607.
74. 2 synthetase, on eicosanoid production. Eur J Pharmacol. 2001;422:209-216.
75. Yoshimoto T, Takahashi Y. Arachidonate 12-lipoxygenases. Prostaglandins Other Lipid Mediat. 2002;68-69:245-262.
76. Fujimoto Y, Sakuma S, Tsunomori M, Sumiya T, Fujita T. Sphingomyelin inhibits platelet 12-lipoxygenase activity. Eur J Pharmacol. 1999;378:233-236.
77. Suzuki H, Ueda T, Juranek I, Yamamoto S, Katoh T, Node M, et al. Hinokitiol, a selective inhibitor of the platelet-type isozyme of arachidonate 12-lipoxygenase. Biochem Biophys Res Commun. 2000;275:885-889.
78. Fujimoto Y, Tsunomori M, Muta E, Yamamoto T, Nishida H, Sakuma S, et al. High density lipoprotein inhibits platelet 12-lipoxygenase activity. Res Commun Mol Pathol Pharmacol. 1994;85:355-358.
79. Gorins G, Kuhnert L, Johnson CR, Marnett LJ. (Carboxyalkyl) benzyl propargyl ethers as selective inhibitors of leukocyte-type 12-lipoxygenases. J Med Chem. 1996;39:4871-4878.
80. Moody JS, Marnett LJ. Kinetics of inhibition of leukocyte 12-lipoxygenase by the isoform-specific inhibitor 4-(2-oxapentadeca-4-yne)phenylpropanoic acid. Biochemistry. 2002;41:10297-10303.
81. Bocan TM, Rosebury WS, Mueller SB, Kuchera S, Welch K, Daugherty A, et al. A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit. Atherosclerosis. 1998;136:203-216.
82. Middleton E, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000;52:673-751.
83. 4 and γ-glutamyl amino acids. Proc Natl Acad Sci USA. 1982;79:1088-1091.
84. 4 synthesis in vivo and attenuation of the acute inflammatory response. Mol Cell Biol. 2001;21:5389-5395.
85. 4 formation in vivo. Am J Pathol. 2002;161:481-490.
86. 4 receptor antagonist. Can J Physiol Pharmacol. 1995;73:191-201.
87. Wu AY, Chik SC, Chan AW, Li Z, Tsang KW, Li W. Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma. Clin Exp Allergy. 2003;33:359-366.